• Publications
  • Influence
Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer:
Dose density improves clinical outcomes significantly, despite the lower than expected number of events at this time, and Sequential chemotherapy is as effective as concurrent chemotherapy.
The decrease in breast-cancer incidence in 2003 in the United States.
An initial analysis of data from the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) registries shows that the age-adjusted incidence rate of breast cancer in women in
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.
The addition of four cycles of paclitaxel after the completion of a standard course of CA improves the disease-free and overall survival of patients with early breast cancer.
Effect of screening and adjuvant therapy on mortality from breast cancer
Seven statistical models showed that both screening mammography and treatment have helped reduce the rate of death from breast cancer in the United States.
Benefits and harms of CT screening for lung cancer: a systematic review.
Low-dose computed tomography screening may benefit individuals at an increased risk for lung cancer, but uncertainty exists about the potential harms of screening and the generalizability of results.
Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.
A model for evaluating the probabilities that a woman is a carrier of a mutation of BRCA1 and BRCa2, on the basis of her family history of breast and ovarian cancer in first- and second-degree relatives is developed.
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth
Adding trastuzumab to chemotherapy, as used in this trial, significantly increased pathologic complete response (pCR) rate without clinical congestive heart failure, according to the small sample size.
Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343.
With long-term follow-up, the previously observed small improvement in locoregional recurrence with the addition of radiation therapy remains, however, this does not translate into an advantage in OS, distant disease-free survival, or breast preservation.